Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias

Cardiac arrhythmias can be difficult to diagnose and treat because current mapping systems analyze the heart one chamber at a time. This fragmented view forces clinicians to infer electrical activity they cannot directly observe, potentially missing circuits deep within the heart wall or spanning multiple chambers. Such limitations can prolong procedures and increase complexity during ablation therapy. Researchers have now developed a system capable of simultaneously mapping all four chambers of the heart, delivering a comprehensive, real-time 3D view of arrhythmias.

In a collaborative breakthrough, researchers from the Universitat Politècnica de València (UPV, Valencia, Spain) and the Corify Care (Madrid, Spain) have developed the new platform that visualizes the interior of the heart, including walls and septum, generating a complete map of cardiac electrical activity within a single heartbeat. The patented Global Volumetric Mapping technology evolved from earlier systems that mapped only the heart’s surface. This volumetric approach allows clinicians to observe how arrhythmia propagates through the heart wall and between chambers before and during ablation procedures.

The ACORYS system was evaluated in a multicenter study involving several European clinical and research institutions. The results demonstrated that technology could identify arrhythmia pathways often undetected by conventional tools, including circuits located deep within myocardial tissue. The findings, published in Nature Communications Medicine, validate the first system capable of comprehensive four-chamber mapping in real time, overcoming previous mathematical and technical limitations in arrhythmia characterization.

By eliminating blind spots, the platform may enable faster decision-making, more targeted ablations, and reduced procedural time. Researchers suggest that holistic visualization of arrhythmias could improve workflow efficiency and clinical outcomes in electrophysiology laboratories. The ACORYS system is CE marked and currently under FDA review in the United States. Corify Care is advancing integration with catheter navigation platforms and expanding research into volumetric cardiac analysis to support broader clinical adoption.

“It’s about visibility and confidence. We give doctors the whole picture from the start, not fragments,” said Andreu Climent, PhD, CEO of Corify Care and researcher at Universitat Politècnica de València. A global view means faster decisions, more targeted ablations, and the potential to reduce the time and complexity of the procedure.”

Related Links:
UPV
Corify Care